


**Product Name** : ICEC 0942 hydrochloride  
**Cat. No.** : PC-35095  
**CAS No.** : 1805789-54-1  
**Molecular Formula** : C<sub>22</sub>H<sub>31</sub>ClN<sub>6</sub>O  
**Molecular Weight** : 430.981  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** : 10 mM in DMSO



## Biological Activity

ICEC0942 (Samuraciclib, CT7001) hydrochloride is a potent, selective, orally active **CDK7** inhibitor with IC<sub>50</sub> of 41 nM, displays 15-fold selectivity over CDK2 (IC<sub>50</sub>=578 nM).

ICEC0942 displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2, CDK5 and CDK9.

ICEC0942 demonstrates sensitivity against a wide range of cancer types with GI<sub>50</sub> values ranging between 0.2-0.3 μM.

ICEC0942 shows substantial anti-tumor effects in xenografts of both breast and colorectal cancers, also exhibits complete growth arrest of ER-positive tumor xenografts combined with tamoxifen.

## References

Hazel P, et al. **ChemMedChem**. 2017 Mar 7;12(5):372-380.

Patel H, et al. **Mol Cancer Ther**. 2018 Mar 15. pii: molcanther.0847.2016.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com